CAGLIO, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 221
EU - Europa 153
AS - Asia 99
SA - Sud America 2
AF - Africa 1
Totale 476
Nazione #
US - Stati Uniti d'America 209
IT - Italia 86
SG - Singapore 45
CN - Cina 23
CA - Canada 12
FR - Francia 12
DE - Germania 10
IE - Irlanda 10
GB - Regno Unito 9
ID - Indonesia 7
JP - Giappone 7
SE - Svezia 7
BE - Belgio 6
IN - India 5
VN - Vietnam 4
FI - Finlandia 3
KR - Corea 3
TR - Turchia 3
CH - Svizzera 2
CZ - Repubblica Ceca 2
ES - Italia 2
HK - Hong Kong 2
PE - Perù 2
ET - Etiopia 1
GR - Grecia 1
NL - Olanda 1
PL - Polonia 1
RU - Federazione Russa 1
Totale 476
Città #
Santa Clara 61
Singapore 37
Chandler 22
Turin 15
New York 11
Dublin 10
Milan 9
Columbus 8
Fairfield 8
Paris 8
Jakarta 7
Montreal 7
Nyköping 7
Rome 6
Medford 5
Munich 5
Torino 5
Brussels 4
London 4
Tokyo 4
Wilmington 4
Ashburn 3
Bologna 3
Frankfurt am Main 3
Hangzhou 3
Hebei 3
Hoffman 3
Istanbul 3
Los Angeles 3
Princeton 3
River Edge 3
Seoul 3
Wakagi 3
Acri 2
Bayonne 2
Bhilai 2
Brno 2
Brookline 2
Chengdu 2
Civitella del Tronto 2
Florence 2
Guangzhou 2
Helsinki 2
Lima 2
Liverpool 2
Modena 2
Pamplona 2
Pune 2
San Jose 2
Seattle 2
Toronto 2
Trepuzzi 2
Upper Marlboro 2
Vancouver 2
Woodbridge 2
Zurich 2
Altoona 1
Amsterdam 1
Ancona 1
Beijing 1
Boardman 1
Bolton 1
Boston 1
Burnaby 1
Central 1
Chongqing 1
Dallas 1
Enfield 1
Fabriano 1
Fayetteville 1
Fiumicino 1
Forest City 1
Genoa 1
Houston 1
Hyderabad 1
Krakow 1
Lappeenranta 1
Lyon 1
Macerata 1
Marano di Napoli 1
Melrose 1
Nanjing 1
North Wales 1
Norwalk 1
Osimo 1
Perugia 1
Porto Recanati 1
Rockaway 1
Washington 1
Totale 362
Nome #
Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review 170
Clinical and molecular features of epidermal growth factor receptor (Egfr) mutation positive non‐small‐cell lung cancer (nsclc) patients treated with tyrosine kinase inhibitors (tkis): Predictive and prognostic role of co‐mutations 87
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 79
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study 55
Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020 27
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience 26
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study 25
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study 25
Totale 494
Categoria #
all - tutte 1.881
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.881


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 0 0 0 0 0 0 0 0 0 8
2021/202278 15 5 4 5 3 2 2 0 0 6 21 15
2022/202396 10 11 3 7 4 19 13 9 5 3 12 0
2023/2024114 12 8 5 11 9 10 4 9 2 22 12 10
2024/2025198 46 9 16 30 67 30 0 0 0 0 0 0
Totale 494